Search

Scholarly Works (1 results)

Article
Peer Reviewed

Oncogenic KRAS sensitizes premalignant, but not malignant cells, to Noxa-dependent apoptosis through the activation of the MEK/ERK pathway.

Ashworth, Alan;
Conti, A;
Majorini, MT;
Elliott, R;
Lord, CJ;
Cancelliere, C;
Bardelli, A;
Seneci, P;
Walczak, H;
Delia, D

UC San Francisco Previously Published Works (2015)

KRAS is mutated in about 20-25% of all human cancers and especially in pancreatic, lung and colorectal tumors. Oncogenic KRAS stimulates several pro-survival pathways, but it also triggers the trans-activation of pro-apoptotic genes. In our work, we show t